| Authors: |
Bao Q; Synthetic Product Development, Alexion, AstraZeneca Rare Disease, New Haven, CT, USA. Electronic address: quanying.bao@alexion.com., Clarke JG; Manufacturing Science and Technology, Global Supply Chain, GSK, Ware, UK., Curran DW; Analytical Development, GSK, Collegeville, PA, USA., Duvnjak M; Technical Research & Development, Novartis Pharma AG, Basel, Switzerland., Goyal N; Clinical Pharmacology and Pharmacometrics, Johnson & Johnson, Titusville, NJ, USA., Heimbach T; Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc., Rahway, NJ, USA., Jain KH; Analytical Development and Operations, Gilead Sciences, Foster City, CA, USA., Pawar P; Formulation and Process Development, Gilead Sciences, Foster City, CA, USA., Ragoonanan V; Drug Product Design and Development, AbbVie, Irvine, CA, USA., Saha P; Drug Product Development, GSK, Collegeville, PA, USA., Shaik NA; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., South San Francisco, CA, USA., Vargo R; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., West Point, PA, USA., Wan B; Drug Product Development & Biopharm, Sanofi, Cambridge, MA, USA. |
